ZIM Laboratories Limited

ZIMLAB

INE518E01015

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 03:00:38 2024-05-18 am EDT			5-day change	1st Jan Change
114 ^INR	0.00%		-0.91%	-1.08%

May. 14	Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5%	MT
May. 13	ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

ZIM Laboratories Limited Announces Resignation of Riazahmed Kamal as Whole Time Director, Effective July 01, 2021

June 29, 2021 at 08:02 am EDT

ZIM Laboratories Limited announced that resignation of Mr. Riazahmed Kamal as Whole Time Director due to health and personal issues, which is effective from July 01, 2021.

Latest news about ZIM Laboratories Limited

Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5%	May. 14	MT
ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 13	CI
ZIM Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 29	CI
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 01	CI
Zim Laboratories Arm Gets License to Operate Business in Dubai, UAE	23-10-16	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
ZIM Laboratories Limited agreed to acquire 99% stake in Zimtas Pty Ltd for approximately AUD 0.01 million.	23-06-27	CI
CARE Gives BBB Rating to Zim Laboratories' Long-term Bank Financing; Outlook Stable	23-06-06	MT
ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
ZIM Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-03	CI
ZIM Laboratories Issues Over 32 Million Bonus Shares	22-12-23	MT
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-12	CI
Acuite Retains BBB- Rating on Zim Laboratories' Bank Loans; Raises Outlook to Positive	22-08-30	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-07-26	CI
ZIM Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-21	CI
ZIM Laboratories Limited Announces Grant of Marketing Authorization for Sildenafil Citrate 50 mg Orally Dissolving Film in Spain, Europe	22-05-12	CI
ZIM Laboratories Limited Announces Board Changes, Effective April 1, 2022	22-03-31	CI
ZIM Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-10-30	CI
ZIM Laboratories : Acuite Ratings & Research Upgrades Zim Laboratories' Rating to BBB-; Keeps Stable Outlook	21-09-23	MT
ZIM Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-13	CI
Zim Laboratories' : European Arm Gets Approval to Market Migraine Drug Rizatriptan in Portugal	21-07-04	MT
Zim Laboratories Limited Announces Granting of Marketing Authorization for Rizatriptan Orally Dissolving Film in Portugal	21-07-02	CI
ZIM Laboratories Limited Announces Resignation of Riazahmed Kamal as Whole Time Director, Effective July 01, 2021	21-06-29	CI
Zim Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-05-29	CI

Chart ZIM Laboratories Limited

Duration

Period

More charts

ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZIM LABORATORIES LIMITED	-1.08%	66.68M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.12B
OTSUKA HOLDINGS CO., LTD.	+22.99%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.61B
ZYDUS LIFESCIENCES LIMITED	+60.18%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.35%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals